Jeffrey A. Barnes - Concepedia

Author

Jeffrey A. Barnes

Also Known As

Barnes, Jeffrey, Eytan Cohen, J A Barnes, J. A. Barnes, J. BARNES, J.A. Barnes, Jeffrey A. Barnes, Jeffrey A Barnes, Jeffrey A. Barnes, Jeffrey Barnes

134

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Massachusetts General Hospital Dana-Farber Cancer Institute Harvard University Moffitt Cancer Center Memorial Sloan Kettering Cancer Center

About

Jeffrey A. Barnes is an author at Massachusetts General Hospital specializing in medicine, oncology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	830
2	Health Sciences	5	5	281
3	Natural Sciences	1	1	51
4	Biology	1	1	51
5	Cell Biology	1	1	56

Jeffrey A. Barnes

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells Philipp Karschnia, Justin T. Jordan, Deborah Forst, Blood	2019	329
Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma Jeremy S. Abramson, Matthew D. Hellmann, Jeffrey A. Barnes, Cancer	2010	231
Requirement of Mammalian <i>Timeless</i> for Circadian Rhythmicity Jessica W. Barnes, Shelley A. Tischkau, Jeffrey A. Barnes, Science	2003	207
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai, Journal of the National Comprehensive Cancer Network	2022	153
Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis Jeffrey A. Barnes, Ann S. LaCasce, Yang Feng, Annals of Oncology Hematological MalignancyLymphoid NeoplasiaMedicineMalignant Blood DisorderImmunology	2011	149
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020 Neha Mehta–Shah, Stephen M. Ansell, Weiyun Z. Ai, Journal of the National Comprehensive Cancer Network ImmunologyNccn Guidelines InsightsPathologySystemic TherapyDermatology	2020	115
End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma Jeffrey A. Barnes, Ann S. LaCasce, Katherine Zukotynski, Annals of Oncology Positron Emission TomographyLymphoid NeoplasiaOncologic ImagingMedicineDiagnosis	2010	105
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease Jacob D. Soumerai, Matthew D. Hellmann, Yang Feng, Leukemia & lymphoma/Leukemia and lymphoma Lymphoid NeoplasiaOptimal TherapyRadiation TherapyHigh RateMedicine	2013	84
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018 Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai, Journal of the National Comprehensive Cancer Network Lymphoid NeoplasiaT-cell LymphomasImmunodeficienciesMedicineImmunology	2018	76
Phase 2 trial of high‐dose rituximab with high‐dose cytarabine mobilization therapy and high‐dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non‐Hodgkin lymphoma Yi‐Bin Chen, Tracy T. Batchelor, Shuli Li, Cancer	2014	70

Page 1